Colleagues,
As reported in CNN Money.Com...Garnet Biotherapeutics, a regenerative medicine company developing products that speed healing and reduce scarring after surgery or dermatologic procedures, today announced the close of a $10.4 million round led by SCP Vitalife Partners II, L.P. Garnet will use the proceeds to fund Phase II clinical trials of its proprietary human adult bone marrow-derived cells, as well as manufacturing and development. Safeguard Scientifics, Inc. and Alliance Technology Ventures also participated in the financing.
Read on at:
http://money.cnn.com/news/newsfeeds/articles/marketwire/0470840.htm
Tags: